What is Cantonbio?
Founded in 2016, Cantonbio has established itself as a specialized player in the development and manufacturing of monoclonal antibodies, bispecific antibodies, and therapeutic recombinant proteins. Headquartered in Guangzhou, China, with strategic international operations in Switzerland, the company operates a sophisticated infrastructure that adheres to FDA, EMA, and Chinese cGMP standards. The organization distinguishes itself through a dual-focus approach: maintaining a high-efficiency R&D platform while simultaneously providing contract manufacturing organization (CMO) services. With a workforce characterized by high academic attainment and a management team comprised of international industry veterans, Cantonbio is effectively bridging the gap between complex biological research and large-scale commercial production.
How much funding has Cantonbio raised?
Cantonbio has raised a total of $41M across 1 funding round:
Series C
$41M
Series C (2023): $41M with participation from Chnin Financial, Taipu Life Science Investment, Guangdong Technology Financial Group, and SDIC Venture Capital
Key Investors in Cantonbio
SDIC Venture Capital
A specialized venture capital firm focusing on advanced manufacturing, electronic information, and the biomedicine sector to foster technological innovation.
Chnin Financial
A financial institution providing strategic capital and investment support to high-growth enterprises within the Chinese market.
Taipu Life Science Investment
An investment entity dedicated to the life sciences sector, providing targeted funding for biotechnology and pharmaceutical development.
What's next for Cantonbio?
With the recent infusion of capital, Cantonbio is expected to prioritize the expansion of its Foshan-based R&D and production facilities. The strategic roadmap likely involves deepening its pipeline of bispecific antibodies, which represent a high-growth segment in oncology and immunology. Furthermore, the company is poised to leverage its international subsidiary to facilitate cross-border collaborations and regulatory navigation, ensuring that its therapeutic candidates meet the stringent requirements of Western markets. As the firm transitions into this next phase of growth, the focus will remain on optimizing production efficiency and securing additional partnerships to solidify its status as a premier biopharmaceutical platform in South China.
See full Cantonbio company page
